Literature DB >> 27922497

Autoimmune Myopathies.

Andrew L Mammen.   

Abstract

PURPOSE OF REVIEW: This article provides guidelines for diagnosing and treating the different subtypes of autoimmune myopathies. RECENT
FINDINGS: The most common subtypes of autoimmune myopathies are dermatomyositis, immune-mediated necrotizing myopathy, antisynthetase syndrome, and overlap syndromes; isolated polymyositis is an exceptionally rare disease. Specific autoantibodies are associated with unique clinical phenotypes and may be used for diagnostic and prognostic purposes, such as to assess the risk of coexisting malignancy.
SUMMARY: Diagnosing the specific subtype of autoimmune myopathy can be achieved by combining relevant features of the history, neuromuscular examination, muscle biopsy, and serologic studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27922497      PMCID: PMC5898966          DOI: 10.1212/01.CON.0000511070.50715.ab

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  49 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Unicorns, dragons, polymyositis, and other mythological beasts.

Authors:  Anthony A Amato; Robert C Griggs
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

3.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

4.  Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis.

Authors:  S Roux; H P Seelig; O Meyer
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

5.  Identification of clinical features and autoantibodies associated with calcinosis in dermatomyositis.

Authors:  Antonia Valenzuela; Lorinda Chung; Livia Casciola-Rosen; David Fiorentino
Journal:  JAMA Dermatol       Date:  2014-07       Impact factor: 10.282

Review 6.  Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis.

Authors:  Andrew L Mammen
Journal:  Nat Rev Neurol       Date:  2011-06-08       Impact factor: 42.937

7.  Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.

Authors:  Andrew L Mammen; Katherine Pak; Emma K Williams; Diane Brisson; Joe Coresh; Elizabeth Selvin; Daniel Gaudet
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

8.  Cancer-associated myositis: clinical features and prognostic signs.

Authors:  Andrea Ponyi; Tamás Constantin; Miklós Garami; Csilla András; Béla Tállai; Andrea Váncsa; Lajos Gergely; Katalin Dankó
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

9.  Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience.

Authors:  Martin Klein; Heřman Mann; Lenka Pleštilová; Josef Zámečník; Zoe Betteridge; Neil McHugh; Jiří Vencovský
Journal:  Rheumatology (Oxford)       Date:  2015-06-24       Impact factor: 7.580

10.  Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.

Authors:  Sarah L Tansley; Zoe E Betteridge; Gavin Shaddick; Harsha Gunawardena; Katie Arnold; Lucy R Wedderburn; Neil J McHugh
Journal:  Rheumatology (Oxford)       Date:  2014-07-01       Impact factor: 7.580

View more
  6 in total

1.  Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.

Authors:  Dirk Essers; Martina Schäublin; Gerd A Kullak-Ublick; Stefan Weiler
Journal:  Eur J Clin Pharmacol       Date:  2018-11-15       Impact factor: 2.953

Review 2.  The manifestation of myositis in tick-borne encephalitis as a prophet of severe disease course: a rare case report.

Authors:  Marija Montvydaite; Goda Seskute; Gabriele Minseviciute; Linas Svetikas; Dalia Miltiniene; Sandra Selickaja; Irena Butrimiene
Journal:  Clin Rheumatol       Date:  2022-01-13       Impact factor: 2.980

3.  A rare overlap of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A necrotizing autoimmune myositis and dermatomyositis.

Authors:  Priya Parikh; Nneoma Onuorah; Priyanka Vashisht
Journal:  Rheumatol Adv Pract       Date:  2021-08-23

Review 4.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 5.  Inclusion body myositis: clinical features and pathogenesis.

Authors:  Steven A Greenberg
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

6.  Aggressive and fatal statin-induced dermatomyositis: a case report.

Authors:  Raíssa Massaia Londero Chemello; Ana Maria Benvegnú; Lia Natália Diehl Dallazem; Diego Chemello
Journal:  Oxf Med Case Reports       Date:  2017-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.